These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 32065376)

  • 1. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.
    Gillessen A; Schmidt HH
    Adv Ther; 2020 Apr; 37(4):1279-1301. PubMed ID: 32065376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of silymarin in the treatment of liver diseases.
    Saller R; Meier R; Brignoli R
    Drugs; 2001; 61(14):2035-63. PubMed ID: 11735632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.
    Pradhan SC; Girish C
    Indian J Med Res; 2006 Nov; 124(5):491-504. PubMed ID: 17213517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
    Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
    Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatoprotective properties of silymarin].
    Matveev AV; Koniaeva EI; Kurchenko VP; Shchekatikhina AS
    Eksp Klin Gastroenterol; 2011; (2):130-5. PubMed ID: 21560654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Milk thistle.
    Rainone F
    Am Fam Physician; 2005 Oct; 72(7):1285-8. PubMed ID: 16225032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Silymarin in the treatment of chronic liver diseases: past and future].
    Fehér J; Lengyel G
    Orv Hetil; 2008 Dec; 149(51):2413-8. PubMed ID: 19073452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.
    Jaffar HM; Al-Asmari F; Khan FA; Rahim MA; Zongo E
    Food Sci Nutr; 2024 May; 12(5):3097-3111. PubMed ID: 38726410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Liverubin™ on hepatic biochemical profile in patients of alcoholic liver disease: a retrospective study.
    Nanda V; Gupta V; Sharma SN; Pasricha A; Karmakar AK; Patel A; Bhatt VM; Kantroo BL; Kumar B; Paul NK; Attam R
    Minerva Med; 2014 Dec; 105(6 Suppl 2):1-8. PubMed ID: 26076375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silymarin: a review of its clinical properties in the management of hepatic disorders.
    Wellington K; Jarvis B
    BioDrugs; 2001; 15(7):465-89. PubMed ID: 11520257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Silibinin and its hepatoprotective action from the perspective of a toxicologist].
    Kostek H; Szponar J; Tchórz M; Majewska M; Lewandowska-Stanek H
    Przegl Lek; 2012; 69(8):541-3. PubMed ID: 23243923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis.
    de Avelar CR; Pereira EM; de Farias Costa PR; de Jesus RP; de Oliveira LPM
    World J Gastroenterol; 2017 Jul; 23(27):5004-5017. PubMed ID: 28785154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.
    Federico A; Dallio M; Loguercio C
    Molecules; 2017 Jan; 22(2):. PubMed ID: 28125040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [[The Pathogenetic Approaches to the Chronic Liver Diseases Treatment].].
    Golovanova EV
    Eksp Klin Gastroenterol; 2016; (5):65-73. PubMed ID: 28614647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated systematic review with meta-analysis for the clinical evidence of silymarin.
    Saller R; Brignoli R; Melzer J; Meier R
    Forsch Komplementmed; 2008 Feb; 15(1):9-20. PubMed ID: 18334810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Silymarin on Diabetes Mellitus Complications: A Review.
    Stolf AM; Cardoso CC; Acco A
    Phytother Res; 2017 Mar; 31(3):366-374. PubMed ID: 28124457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silymarin in the prevention and treatment of liver diseases and primary liver cancer.
    Féher J; Lengyel G
    Curr Pharm Biotechnol; 2012 Jan; 13(1):210-7. PubMed ID: 21466434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular).
    Rosso N; Marin V; Giordani A; Persiani S; Sala F; Cavicchioli L; Rovati LC; Tiribelli C
    Curr Med Chem; 2015; 22(25):2954-71. PubMed ID: 26219393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
    Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
    J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free Radical-Scavenging, Anti-Inflammatory/Anti-Fibrotic and Hepatoprotective Actions of Taurine and Silymarin against CCl4 Induced Rat Liver Damage.
    Abdel-Moneim AM; Al-Kahtani MA; El-Kersh MA; Al-Omair MA
    PLoS One; 2015; 10(12):e0144509. PubMed ID: 26659465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.